Clinical trials: Chronic Obstructive Pulmonary
Chronic Obstructive Pulmonary Disease
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Primary Objective: Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD Secondary Objectives: Evaluate the…
- Trial name
- AERIFY-1 (NCT04701983)
- Testing
- Itepekimab SAR440340
- Where
- 232 sites in United States, Argentina and 19 more
- Volunteers
- 1,127 people
- Sponsor
- Sanofi
Dementia, Chronic Disease
Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2)
The objective of this protocol is to test the effectiveness of a Jumpstart intervention on patient-centered outcomes for patients with chronic illness by ensuring that they receive care that is concordant with their goals over…
- Conditions
- Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasms
- Trial name
- PICSI-H (NCT04283994)
- Testing
- Survey-based Patient/Clinician Jumpstart, EHR-based Clinician Jumpstart
- Where
- 3 sites in United States
- Volunteers
- 756 people
- Sponsor
- University of Washington
Pulmonary Disease, Chronic Obstructive
Comparative Effectiveness of COPD Treatments
To assess the effectiveness of maintenance treatment of Chronic obstructive pulmonary disease (COPD) with the combination of a long-acting bronchodilators (LABA and the long-acting muscarinic antagonists (LAMA) tiotropium…
- Trial name
- NCT03376295
- Testing
- LABA and the LAMA tiotropium (LABA-TIO), LABA and an ICS (LABA-ICS)
- Where
- Canada
- Volunteers
- 3,954 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Metformin to Reduce Airway Glucose in COPD Patients
Chronic obstructive pulmonary disease (COPD) is the 4th leading cause of death worldwide and affects 1.2 million people in the UK, costing the NHS >£800 million annually.
- Trial name
- NCT03651895
- Testing
- Metformin
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Imperial College London
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)
This is a two-part study conducted at multiple centers, of navarixin (SCH 527123, MK-7123) in participants with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00441701
- Testing
- Navarixin 1 mg, Navarixin 10 mg, Rescue medication
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Asthma, COPD
Teaching Use of Respiratory Inhalers (TURI)
The purpose of this study is to evaluate the feasibility of enrolling and randomizing patients into one of two educational interventions to teach appropriate respiratory inhaler technique and to collect preliminary estimates of…
- Trial name
- TURI (NCT01456494)
- Testing
- Brief Intervention, Teach-to-Goal Education
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Chicago
Chronic Obstructive Pulmonary Disease (COPD)
A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD
This is a long-term safety trial of 48 weeks. Eligible subjects will enter the 48-week, open-label treatment period to receive one of two treatments (SUN-101 given as 50 mcg twice a day or Spiriva® [tiotropium] given as 18 mcg…
- Trial name
- GOLDEN-5 (NCT02276222)
- Testing
- SUN-101 50 mcg BID eFlow (CS) nebulizer, Spiriva® 18 mcg QD Handihaler
- Where
- 118 sites in United States, Czechia and 2 more
- Volunteers
- 1,087 people
- Sponsor
- Sunovion Respiratory Development Inc.
COPD, COPD Exacerbation
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD.
- Conditions
- COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders
- Trial name
- NCT01443845
- Testing
- Roflumilast
- Where
- 338 sites in United States, Argentina and 15 more
- Volunteers
- 2,354 people
- Sponsor
- AstraZeneca
Chronic GVHD
Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
Background: Chronic Graft Versus Host Disease (cGVHD) can occur after a person has had a stem cell or bone marrow transplant. In cGVHD, the donor cells attack the recipient's body.
- Trial name
- NCT04294641
- Testing
- Ibrutinib, ECG, PFT's
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease
Right Ventricular Hemodynamics Using Cardiac MRI in Patients COPD and OSA
The coexistence of chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) in the same patient has been termed overlap syndrome, affecting 1% of the U.S.
- Conditions
- Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease, Overlap Syndrome
- Trial name
- NCT02244957
- Testing
- Bi-level positive airway pressure (BPAP), Nocturnal oxygen
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of California, San Diego
Chronic Cough, Eosinophilic Bronchitis
Mepolizumab for the Treatment of Chronic Cough With Eosinophilic Airways Diseases
Cough is the most common presenting symptom to family physician. Chronic Cough affects approximately 10-12% of the general population and is one of the commonest reasons for referral to secondary care.
- Conditions
- Chronic Cough, Eosinophilic Bronchitis, Asthma
- Trial name
- MUCOSA (NCT04765722)
- Testing
- Mepolizumab, Normal Saline
- Where
- Canada
- Volunteers
- 46 people
- Sponsor
- McMaster University
Asthma, COPD
Can we Reduce Hospital Attendance Without Compromising Care by the Use of Telephone Consultation
Consultation time in busy respiratory clinics is inevitably limited and attendance is often disruptive to patients' lives; involves time, expense, travel, and waiting; and can have effects upon occupation.
- Conditions
- Asthma, COPD, Sleep Apnea Syndromes, Interstitial Lung Diseases
- Trial name
- NCT00129701
- Testing
- Telephone consultation
- Where
- United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Imperial College London
COPD, Chronic Musculoskeletal Pain
BRAIN, Symptoms, and Physical Activity in COPD
Persons with COPD have both chronic musculoskeletal pain and dyspnea that require accurate diagnosis and treatment, ultimately to optimize functional status.
- Trial name
- BRAIN-SPA (NCT04291131)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- VA Office of Research and Development
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients
The main purpose of this study is to evaluate the efficacy, safety and tolerability of multiple doses of inhaled aclidinium bromide in moderate to severe COPD patients.
- Trial name
- NCT00868231
- Testing
- Aclidinium bromide 400 μg bid, Tiotropium 18 μg once-daily
- Where
- 2 sites in Germany
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD
The study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of the combination of inhaled GSK573719 and GW64244 compared to placebo, in subjects with COPD.
- Trial name
- NCT01039675
- Testing
- 500mcg/25mcg once daily
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD
Patients who are hospitalized at select Carolinas Healthcare System (CHS) sites with Chronic Obstructive Pulmonary Disorder (COPD) acute exacerbation symptoms will be treated per the CHS COPD Clinical Pathway.
- Trial name
- NCT03207776
- Testing
- Usual Care, COPD Clinical Pathway
- Where
- 8 sites in United States
- Volunteers
- 4,832 people
- Sponsor
- Wake Forest University Health Sciences
Chronic Obstructive Pulmonary Disease
Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD
The overall objective of this study was to assess the efficacy and safety of GP MDI relative to placebo in Japanese subjects with moderate to severe COPD.
- Trial name
- NCT03256552
- Testing
- Glycopyrronium MDI 28.8 micrograms, Glycopyrronium MDI 14.4 micrograms, Glycopyrronium MDI 7.2 micrograms
- Where
- 18 sites in Japan
- Volunteers
- 66 people
- Sponsor
- Pearl Therapeutics, Inc.
Pulmonary Disease, Chronic Obstructive
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
The objective of this study is to assess the efficacy and safety of 12 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the Respimat inhaler) compared with tiotropium and placebo in…
- Trial name
- NCT01964352
- Testing
- tiotropium, olodaterol
- Where
- 77 sites in United States, Belgium and 8 more
- Volunteers
- 813 people
- Sponsor
- Boehringer Ingelheim
Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
The objective of this extension protocol is to collect safety data (serious and non-serious adverse events) and to provide continuous canakinumab to patients in France who completed study CACZ885G2301E1(NCT00891046), CACZ885G2306…
- Trial name
- NCT02334748
- Testing
- canakinumab
- Where
- 3 sites in France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Emphysema, Chronic Obstructive Pulmonary Disease (COPD)
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
The purpose of this research study is to learn about the safety of transplanting lungs obtained from non-heart-beating donors (NHBDs) that have been ventilated (attached to a breathing machine or ventilator to deliver oxygen) and…
- Conditions
- Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis
- Trial name
- NCT01615484
- Testing
- Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™, STEEN Solution™
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of North Carolina, Chapel Hill
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.